Published in Cancer Weekly, April 12th, 2005
"Antitumor activity of BAT, muramyldipeptide (MDP) and four immunomodulatory conjugates of BAT with MDP were evaluated in the study. The activity was assessed using viability tests performed in the cultures of tumor cell lines of different tissue origin such as WEHI 164 (fibrosarcoma), K562 (leukaemia), and Ab (melanoma), populations of immune cells isolated from peripheral blood, and the tumor cells mixed with immune cells," wrote P. Trzonkowski and colleagues, Medical Academy of Gdansk.
"An intensity of cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.